Download PDF
CC BY-NC-ND 4.0 · AJP Rep 2021; 11(02): e102-e104
DOI: 10.1055/s-0041-1731311
Case Report

The Effect of Prenatal and Postnatal Treatment with Intravenous Immunoglobulin on Severity of Neonatal Hemochromatosis: The Tale of Two Brothers (Case Report)

Veronica Mugarab-Samedi 
1   Department of Pediatrics, University of Saskatchewan, Saskatoon, Canada
,
Michelle D. Ryan
2   Section of Neonatology, University of Calgary, Calgary, Alberta, Canada
,
Essa Hamdan Al Awad
2   Section of Neonatology, University of Calgary, Calgary, Alberta, Canada
,
Adel Elsharkawy
2   Section of Neonatology, University of Calgary, Calgary, Alberta, Canada
› Author Affiliations Funding Not funded.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Neonatal hemochromatosis (NH) is a rare condition that was the main reason for liver transplantation in infants. With the realization that NH results from the fetal complement-mediated liver injury, intravenous immunoglobulins (IVIG) were successfully introduced for the treatment.

Case Presentation We present two cases of NH from the same family to illustrate the role of antenatal treatment with IVIG in alleviation and possible prevention of this serious morbidity.

Conclusion A prenatal treatment and early postnatal administration of IVIG are effective ways to manage NH that help to reduce the severity of the symptoms, prevent liver failure, and avoid the need for liver transplantation.

Keywords

neonatal hemochromatosis - intravenous immunoglobulin - prenatal treatment - case report

Declarations

Ethics approval and consent to participate: no ethics approval required, informed consent from the patient received.


Consent for Publication

Written informed consent was obtained from the parents for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.


Availability of data and material: available for review.


Authors' Contributions

VMS provided informed consent, collected the data, reviewed the literature, prepared the manuscript preparation, and had direct involvement in patient care.


MR was involved in initial drafting of manuscript, literature review, and had direct involvement in patient care.


EA and AE edited the manuscript and had direct involvement in patient care.


All authors have read and approved the manuscript.




Publication History

Received: 14 March 2020

Accepted: 21 May 2020

Article published online:
30 June 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Murray KF, Kowdley KV. Neonatal hemochromatosis. Pediatrics 2001; 108 (04) 960-964
    CrossrefPubMedGoogle Scholar
  • 2 Sigurdsson L, Reyes J, Kocoshis SA, Hansen TW, Rosh J, Knisely AS. Neonatal hemochromatosis: outcomes of pharmacologic and surgical therapies. J Pediatr Gastroenterol Nutr 1998; 26 (01) 85-89
    CrossrefPubMedGoogle Scholar
  • 3 Feldman AG, Whitington PF. Neonatal hemochromatosis. J Clin Exp Hepatol 2013; 3 (04) 313-320
    CrossrefPubMedGoogle Scholar
  • 4 Taylor SA, Kelly S, Alonso EM, Whitington PF. The effects of gestational alloimmune liver disease on fetal and infant morbidity and mortality. J Pediatr 2018; 196: 123-128.e1
    CrossrefPubMedGoogle Scholar
  • 5 Heissat S, Collardeau-Frachon S, Baruteau J. et al. Neonatal hemochromatosis: diagnostic work-up based on a series of 56 cases of fetal death and neonatal liver failure. J Pediatr 2015; 166 (01) 66-73
    CrossrefPubMedGoogle Scholar
  • 6 Rand EB, Karpen SJ, Kelly S. et al. Treatment of neonatal hemochromatosis with exchange transfusion and intravenous immunoglobulin. J Pediatr 2009; 155 (04) 566-571
    CrossrefPubMedGoogle Scholar
  • 7 Whitington PF, Hibbard JU. High-dose immunoglobulin during pregnancy for recurrent neonatal haemochromatosis. Lancet 2004; 364 (9446): 1690-1698
    CrossrefPubMedGoogle Scholar
  • 8 Pan X, Kelly S, Melin-Aldana H, Malladi P, Whitington PF. Novel mechanism of fetal hepatocyte injury in congenital alloimmune hepatitis involves the terminal complement cascade. Hepatology 2010; 51 (06) 2061-2068
    CrossrefPubMedGoogle Scholar
  • 9 Whitington PF, Kelly S. Outcome of pregnancies at risk for neonatal hemochromatosis is improved by treatment with high-dose intravenous immunoglobulin. Pediatrics 2008; 121 (06) e1615-e1621
    CrossrefPubMedGoogle Scholar
  • 10 Tanaka H, Haba R, Itoh S, Sakamoto H, Hata T. Prenatal high-dose immunoglobulin treatment for neonatal hemochromatosis: a case report and review of the literature. J Obstet Gynaecol Res 2011; 37 (12) 1891-1894
    CrossrefPubMedGoogle Scholar
  • 11 Jimenez-Rivera C, Gupta A, Feberova J, de Nanassy JA, Boland MP. Successful treatment of neonatal hemochromatosis as gestational alloimmune liver disease with intravenous immunoglobulin. J Neonatal Perinatal Med 2014; 7 (04) 301-304
    CrossrefPubMedGoogle Scholar
  • 12 Babor F, Hadzik B, Stannigel H, Mayatepek E, Hoehn T. Successful management of neonatal hemochromatosis by exchange transfusion and immunoglobulin: a case report. J Perinatol 2013; 33 (01) 83-85
    CrossrefPubMedGoogle Scholar